

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

How common is sensorineural hearing loss after neonatal meningitis?

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001601
Article Type:	Original research letter
Date Submitted by the Author:	05-Jul-2022
Complete List of Authors:	Sharma, Ankur; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit Leaf, James; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Thomas, Saumya; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit Cane, Christine; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Stuart, Claire; Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department Tremlett, Catherine; Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department Fitzgerald, John; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Clarke, Paul; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit; University of East Anglia, Medical School
Keywords:	Audiology, Deafness, Neonatology, Microbiology, Epidemiology

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

TITLE:

How common is sensorineural hearing loss after neonatal meningitis?

AUTHORS:

Ankur Sharma ¹ MRCPCH

James M Leaf ² MSc

Saumya Thomas ¹ MRCPCH

Christine Cane ²

Claire Stuart ³

Catherine Tremlett ³ MD MSc FRCPath

John Fitzgerald ² PhD BSc CS PFBSA

Paul Clarke ^{1,4} MD FRCPCH MRCP(UK)

Affiliations:

1. Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit, Norwich, UK

2. Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology, Norwich, UK

3. Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department, Norwich, UK

4. Norwich Medical School, University of East Anglia, Norwich, UK

Correspondence to: Prof P Clarke, ORCID ID: 0000-0001-6203-7632

Consultant Neonatologist, Neonatal Intensive Care Unit, Norfolk and Norwich University

Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK. Email: paul.clarke@nnuh.nhs.uk

Tel: 01603 286337

Word count: 592

ABSTRACT

Babies in intensive care are at higher risk for meningitis and sensorineural hearing loss (SNHL). The rate of SNHL associated with neonatal meningitis is unclear. We undertook a retrospective review of admissions to our neonatal intensive care unit over a 16-year period (2006-2021). We identified only 16 definite meningitis cases among 16,070 admissions, an incidence of 0.1%. Diagnostic audiology showed 80% (8/10) surviving infants tested had normal/satisfactory hearing while 20% (2/10) had SNHL: both were extremely preterm and received potentially-ototoxic antimicrobials. Larger studies are needed to clarify whether SNHL occurs mainly due to meningitis itself or its antimicrobial drug treatment.

1
2
3 Neonatal meningitis is a well-recognised risk factor for sensorineural hearing loss
4 (SNHL).[1] Meningitis indicates automatic referral for formal audiological testing at age 8
5
6 months in the UK.[2] There are no recent UK data reporting detailed hearing outcomes of
7
8 neonates who suffered neonatal meningitis. Our aim was to study the incidence of SNHL in
9
10 neonates admitted to our tertiary-level neonatal intensive care unit (NICU) with proven
11
12 meningitis.
13
14
15

16
17 We reviewed electronic neonatal records (BadgerNet, Clevermed, UK) and our local
18
19 microbiology database for the 16-year period 1/1/2006 to 31/12/2021 to identify all neonates
20
21 diagnosed with unequivocal bacterial or fungal meningitis. We defined proven meningitis
22
23 cases as those with positive bacterial or fungal growth on culture of cerebrospinal fluid (CSF)
24
25 obtained from infants with clinical signs of suspected meningitis/sepsis and who had received
26
27 at least 2 weeks of antibiotic therapy for the episode. We excluded any neonates with
28
29 meningitis who were never admitted to our NICU and also those treated for suspected
30
31 meningitis despite a negative CSF culture. Babies with CSF isolates of a coagulase-negative
32
33 Staphylococcus plus a concomitant CSF leucocyte count $<20 \times 10^6/L$ were considered false
34
35 positive cases and so also excluded.[3] For all confirmed cases we reviewed isolates,
36
37 concomitant blood cultures, CSF cell counts, newborn hearing screening results, and later
38
39 diagnostic audiological testing at 0.5, 1, 2, and 4 kHz pure tone audiometry thresholds. SNHL
40
41 was diagnosed for infants with hearing loss thresholds >20 dB.[4]
42
43
44
45

46
47 We had 16,070 neonatal admissions to our NICU during the 16-year study period.
48
49 Twenty-eight babies had a culture-positive CSF result and of these 16 were confirmed as
50
51 definite meningitis cases (Table). Overall, the definite meningitis rate was 16/16,070 (0.1%),
52
53 or 1 case per 1000 admissions. Fifteen were bacterial meningitis cases and one fungal. Three
54
55 babies had meningitis caused by a Coagulase-negative Staphylococcus. All except four
56
57 babies (cases 8, 9, 12, 16) had concomitant blood cultures positive with the same organism.
58
59
60

1
2
3 CSF specimens showed very wide variation in white to red blood cell ratios. The incidence of
4
5 meningitis was three-fold higher among preterm compared with term admissions, 12/7,185
6
7 (0.17%) vs. 4/8,885 (0.05%), $p=0.02$, Chi² test). Two infants did not undergo newborn
8
9 hearing screening (1 deceased, 1 contraindicated). Of 14 who underwent the screening, 9/14
10
11 (64%) had clear responses and 5/14 (36%) required referral (1 bilateral, 4 unilateral screen
12
13 fails).
14
15

16
17 Definitive follow-up audiology outcomes were unavailable for six babies (2 died in
18
19 infancy before completion of diagnostic testing; 2 had no formal testing despite meningitis
20
21 history; 2 failed to attend appointments).
22
23

24
25 Diagnostic audiology outcome data were available for 10/14 (71%) surviving infants:
26
27 8/10 (80%) had hearing within normal limits (normal/satisfactory); 2/10 (20%) have SNHL
28
29 (1 severe bilateral; 1 moderate mixed bilateral), a rate of SNHL among surviving neonatal
30
31 meningitis cases of at least 14% (2/14) (95% confidence limits: 2%, 43%). Both SNHL cases
32
33 were infants born extremely preterm at 24 weeks' gestation who suffered meningitis in their
34
35 second postnatal week: one had fungal meningitis caused by *Candida albicans*; one had
36
37 bacterial meningitis caused by *Staphylococcus epidermidis*. Their antimicrobial treatments
38
39 included the potentially-ototoxic agents flucytosine, vancomycin, and rifampicin.
40
41

42
43 Our single centre series covering a 16-year period showed that the incidence of
44
45 definite neonatal meningitis among neonatal admissions was very low overall. SNHL caused
46
47 by neonatal meningitis (or its treatment) was relatively rare, with only two confirmed cases in
48
49 16 years in our NICU. However, for cases of proven meningitis, the associated rate of SNHL
50
51 was not insignificant (at least 14%). Larger studies are required to clarify whether SNHL
52
53 occurs mainly due to meningitis itself, or to its antimicrobial drug treatment in extremely
54
55 preterm neonates.
56
57
58
59
60

Contributorship

PC devised this project. AS, ST and PC collected clinical data, JML, CC, and JF collected audiological data, and CS interrogated the microbiological database. PC and CT reviewed and adjudicated the meningitis cases, and JF provided audiological expertise. PC analysed the data. PC and AS wrote the first manuscript draft and PC wrote the final draft. All authors contributed to manuscript revisions. PC is guarantor.

Patient and Public Involvement statement

The research question arose as a direct result of a parent's question.

Funding

The authors declared no specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

The authors have no relevant competing interests to declare.

Ethics approval

This study reviewed routinely collected clinical data and did not require formal ethics review.

Exclusive License

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has

1
2
3 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for
4
5 US Federal Government officers or employees acting as part of their official duties; on a
6
7 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”)
8
9
10 its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the
11
12 Journal, to publish the Work in BMJ Paediatrics Open and any other BMJ products and to
13
14 exploit all rights, as set out in our [licence](#).
15
16
17
18

19 The Submitting Author accepts and understands that any supply made under these terms is
20
21 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of
22
23 your employer or a postgraduate student of an affiliated institution which is paying any
24
25 applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting
26
27 Author wishes to make the Work available on an Open Access basis (and intends to pay the
28
29 relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
30
31 Commons licence – details of these licences and which [Creative Commons](#) licence will apply
32
33 to this Work are set out in our licence referred to above.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table: CSF isolates, microscopy, and hearing outcomes of 16 neonates with definite meningitis

Case No.	Birth gestation, weeks	Postnatal age, days	CSF isolate	CSF cell count, x10 ⁶ /L		CSF ratio WCC:RCC	Audiological Outcome*
				WBC (% polymorphs)	RBC		
1	24	8	<i>Candida albicans</i>	100 (75%)	21600	1:216	Severe bilateral SNHL
2	24	39	Group B Streptococcus	840 (90%)	7580	1:135	N/A
3	24	8	<i>Staphylococcus epidermidis</i>	56 (0%)	7540	1:135	Moderate mixed bilateral permanent hearing loss
4	24	9	<i>Pseudomonas aeruginosa</i>	4970 (80%)	850	1:0.17	Satisfactory†
5	25	61	<i>Escherichia coli</i>	7420 (75%)	390	1:0.05	N/A (died, untested)
6	25	15	Coagulase-negative Staphylococcus‡	398 (75%)	4580	1:12	Normal
7	27	13	<i>Escherichia coli</i>	3180 (90%)	360	1:0.11	N/A
8	27	25	<i>Enterobacter cloacae complex</i>	18 (5%)	4320	1:240	N/A (died, prior testing attempts unsuccessful)
9	28	30	<i>Escherichia coli</i>	6 (% N/A)	6	1:1	Satisfactory§
10	29	89	Group B Streptococcus	650 (80%)	2220	1:3	N/A
11	31	40	<i>Escherichia coli</i>	3210 (95%)	2	1:6x10 ⁻⁴	Normal
12	36	6	<i>Escherichia coli</i>	960 (60%)	690	1:0.72	Satisfactory†
13	40	8	Group B Streptococcus	2030 (30%)	11310	1:6	Satisfactory†
14	40	2	Group B Streptococcus	10 (% N/A)	5500	1:550	Normal
15	41	5	Group B Streptococcus	2850 (40%)	1300	1:0.46	N/A
16	41	49	<i>Staphylococcus haemolyticus</i>	620 (90%)	2830	1:5	Satisfactory§

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

CSF, cerebrospinal fluid; WCC, white blood cell count; RCC, red blood cell count; SNHL, sensori-neural hearing loss; N/A, test not available (not done or lost to follow up before determined).

*Normal hearing ≤ 20 dB; mild hearing loss 21-40 dB minimum detectable threshold; moderate 41-70 dB; severe loss 71-95 dB; profound loss >95 dB

†Satisfactory hearing, based on oto-acoustic emissions and visual reinforcement audiometry with sound field testing down to 25 dB (no audiogram), unable to rule out mild loss

‡not further specified;

§Satisfactory hearing based on tone pip auditory brainstem responses/oto-acoustic emissions (no audiogram)

Confidential: For Review Only

References

1. Stevens JP, Eames M, Kent A, et al. Long term outcome of neonatal meningitis. *Arch Dis Child Fetal Neonatal Ed.* 2003;88:F179-84. doi: 10.1136/fn.88.3.f179.
2. Public Health England. Guidelines for surveillance and audiological referral for infants and children following newborn hearing screen (Updated 19 July 2019) [Internet]. Available from: <https://www.gov.uk/government/publications/surveillance-and-audiological-referral-guidelines/guidelines-for-surveillance-and-audiological-referral-for-infants-and-children-following-newborn-hearing-screen> [Last accessed 2022 Jul 5]
3. Ku LC, Boggess KA, Cohen-Wolkowicz M. Bacterial meningitis in infants. *Clin Perinatol.* 2015;42:29-45, vii-viii. doi: 10.1016/j.clp.2014.10.004.
4. Paludetti G, Conti G, DI Nardo W, et al. Infant hearing loss: from diagnosis to therapy Official Report of XXI Conference of Italian Society of Pediatric Otorhinolaryngology. *Acta Otorhinolaryngol Ital.* 2012;32:347–70.

Review Only

BMJ Paediatrics Open

Sensorineural hearing loss after neonatal meningitis: a single centre retrospective study

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001601.R1
Article Type:	Original research letter
Date Submitted by the Author:	16-Aug-2022
Complete List of Authors:	Sharma, Ankur; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit Leaf, James; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Thomas, Saumya; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit Cane, Christine; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Stuart, Claire; Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department Tremlett, Catherine; Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department Fitzgerald, John; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Clarke, Paul; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit; University of East Anglia, Medical School
Keywords:	Audiology, Deafness, Neonatology, Microbiology, Epidemiology

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

TITLE:

Sensorineural hearing loss after neonatal meningitis: a single centre retrospective study

AUTHORS:

Ankur Sharma ¹ MRCPCH

James M Leaf ² MSc

Saumya Thomas ¹ MRCPCH

Christine Cane ²

Claire Stuart ³

Catherine Tremlett ³ MD MSc FRCPath

John Fitzgerald ² PhD BSc CS PFBSA

Paul Clarke ^{1,4} MD FRCPCH MRCP(UK)

Affiliations:

1. Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit, Norwich, UK

2. Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology, Norwich, UK

3. Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department, Norwich, UK

4. Norwich Medical School, University of East Anglia, Norwich, UK

Correspondence to: Prof P Clarke, ORCID ID: 0000-0001-6203-7632

Consultant Neonatologist, Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK. Email: paul.clarke@nnuh.nhs.uk

Tel: 01603 286337

Word count: 633

ABSTRACT

Babies in intensive care are at higher risk for meningitis and sensorineural hearing loss (SNHL). We reviewed the rate of SNHL among definite cases of bacterial/fungal meningitis in our neonatal intensive care unit over a 16-year period (2006-2021). We identified 16 confirmed meningitis cases among 16,070 admissions: 8 of 10 surviving infants with available diagnostic audiology had normal/satisfactory hearing while 2 of 10 had SNHL. Both infants with permanent hearing loss had been born extremely preterm and received potentially-ototoxic antimicrobials. Larger studies are needed to clarify whether SNHL occurs mainly due to meningitis itself or to its antimicrobial drug treatment.

1
2
3 Neonatal meningitis is a well-recognised risk factor for sensorineural hearing loss
4 (SNHL),[1] and indicates automatic referral for early auditory brainstem response testing and
5 other formal audiological testing.[2] There are no recent UK data reporting detailed hearing
6 outcomes of neonates who suffered neonatal meningitis. Our aim was to study the incidence
7 of SNHL in neonates admitted to our tertiary-level neonatal intensive care unit (NICU) with
8 proven meningitis.
9

10
11 We reviewed electronic neonatal records (BadgerNet, Clevermed, UK) and our local
12 microbiology database for the 16-year period 1/1/2006 to 31/12/2021 to identify all neonates
13 diagnosed with unequivocal bacterial or fungal meningitis. We defined proven meningitis
14 cases as those with positive bacterial or fungal growth on culture of cerebrospinal fluid (CSF)
15 obtained from infants with clinical signs of suspected meningitis/sepsis and who had received
16 at least 2 weeks of antibiotic therapy for the episode. We excluded any neonates with
17 meningitis who were never admitted to our NICU, those treated for suspected meningitis
18 despite a negative CSF culture, and cases of viral meningitis. Babies with CSF isolates of a
19 coagulase-negative Staphylococcus plus a concomitant CSF leucocyte count $<20 \times 10^6/L$ were
20 considered false positive cases and also excluded.[3] For all confirmed cases we reviewed
21 isolates, concomitant blood cultures, CSF cell counts, newborn hearing screening results, and
22 later diagnostic audiological testing at 0.5, 1, 2, and 4 kHz pure tone audiometry thresholds.
23 SNHL was diagnosed for infants with hearing loss thresholds >20 decibels.[4]
24
25

26 We had 16,070 neonatal admissions to our NICU during the 16-year study period.
27
28 Twenty-eight babies had a culture-positive CSF result and of these 16 were confirmed as
29 definite meningitis cases (Summary Table). Twelve infants were born preterm (cases 1-12)
30 and four were born at term (cases 13-16). Overall, the definite meningitis rate was 16/16,070
31 (0.1%), or 1 case per 1000 admissions. Fifteen were bacterial meningitis cases and one
32 fungal. Three babies had meningitis caused by a Coagulase-negative Staphylococcus. All
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 except four babies (cases 8, 9, 12, 16) had concomitant blood cultures positive with the same
4 organism. CSF specimens showed very wide variation in white to red blood cell ratios. The
5 incidence of meningitis was three-fold higher among preterm compared with term
6 admissions, 12/7,185 vs. 4/8,885, $p=0.02$, Chi² test). Two infants did not undergo newborn
7 hearing screening (1 deceased, 1 contraindicated). Of 14 who underwent the screening, 9 had
8 clear responses and 5 required referral (1 bilateral, 4 unilateral screen fails).
9

10
11
12
13
14
15
16
17 Definitive follow-up audiology outcomes were unavailable for six babies (2 died in
18 infancy before completion of diagnostic testing; 2 had no formal testing despite meningitis
19 history; 2 failed to attend appointments).
20
21
22

23
24 Diagnostic audiology outcome data were available for 10 of the 14 surviving infants:
25
26 8 had hearing within normal limits (normal/satisfactory), and 2 have SNHL (1 severe
27 bilateral; 1 moderate mixed bilateral). Both SNHL cases (cases 1 and 3) were infants born
28 extremely preterm who had suffered meningitis in their second postnatal week: one had
29 fungal meningitis caused by *Candida albicans*; one had bacterial meningitis caused by
30 *Staphylococcus epidermidis*. Their antimicrobial treatments included the potentially-ototoxic
31 agents flucytosine, vancomycin, and rifampicin.
32
33
34
35
36
37
38
39

40
41 Our single-centre series covering a 16-year period showed that the incidence of
42 definite neonatal meningitis among neonatal admissions was very low overall. SNHL caused
43 by neonatal meningitis (or its treatment) was relatively rare, with only two confirmed cases in
44 16 years in our NICU. However, for cases of proven meningitis, the associated rate of SNHL
45 was not insignificant. A large epidemiological study, for example one linking meningitis
46 cases contained in large infection surveillance databases with hearing outcomes as logged in
47 national audiological databases would provide a more accurate indication of SNHL risk after
48 neonatal meningitis. Such linking, along with related biochemical antimicrobial therapeutic
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 drug monitoring data, may also help to clarify whether SNHL occurs mainly due to
4
5 meningitis itself or to its antimicrobial drug treatment in extremely preterm neonates.
6
7
8
9

10 **Contributorship**

11
12 PC devised this project. AS, ST and PC collected clinical data, JML, CC, and JF collected
13
14 audiological data, and CS interrogated the microbiological database. PC and CT reviewed
15
16 and adjudicated the meningitis cases, and JF provided audiological expertise. PC analysed the
17
18 data. PC and AS wrote the first manuscript draft and PC wrote the final draft. All authors
19
20 contributed to manuscript revisions. PC is guarantor.
21
22
23
24
25

26 **Patient and Public Involvement statement**

27
28 The research question arose as a direct result of a parent's question.
29
30
31
32

33 **Funding**

34
35 The authors declared no specific grant for this research from any funding agency in the
36
37 public, commercial or not-for-profit sectors.
38
39
40
41

42 **Competing interests**

43
44 The authors have no relevant competing interests to declare.
45
46
47
48

49 **Ethics approval**

50
51 This study reviewed routinely collected clinical data and did not require formal ethics review.
52
53
54
55

56 **Exclusive License**

1
2
3 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
4 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
5
6 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
7
8 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for
9
10 US Federal Government officers or employees acting as part of their official duties; on a
11
12 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”)
13
14 its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the
15
16 Journal, to publish the Work in BMJ Paediatrics Open and any other BMJ products and to
17
18 exploit all rights, as set out in our [licence](#).
19
20
21
22
23
24
25

26 The Submitting Author accepts and understands that any supply made under these terms is
27
28 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of
29
30 your employer or a postgraduate student of an affiliated institution which is paying any
31
32 applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting
33
34 Author wishes to make the Work available on an Open Access basis (and intends to pay the
35
36 relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
37
38 Commons licence – details of these licences and which [Creative Commons](#) licence will apply
39
40 to this Work are set out in our licence referred to above.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Summary Table: CSF isolates, microscopy, and hearing outcomes of 16 neonates with definite meningitis

Case No.	Postnatal age, days	CSF isolate	CSF cell count, x10 ⁶ /L		CSF ratio WCC:RCC	Audiological Outcome*
			WBC (% polymorphs)	RBC		
1	8	<i>Candida albicans</i>	100 (75%)	21600	1:216	Severe bilateral SNHL
2	39	Group B Streptococcus	840 (90%)	7580	1:135	N/A
3	8	<i>Staphylococcus epidermidis</i>	56 (0%)	7540	1:135	Moderate mixed bilateral permanent hearing loss
4	9	<i>Pseudomonas aeruginosa</i>	4970 (80%)	850	1:0.17	Satisfactory†
5	61	<i>Escherichia coli</i>	7420 (75%)	390	1:0.05	N/A (died, untested)
6	15	Coagulase-negative Staphylococcus‡	398 (75%)	4580	1:12	Normal
7	13	<i>Escherichia coli</i>	3180 (90%)	360	1:0.11	N/A
8	25	<i>Enterobacter cloacae complex</i>	18 (5%)	4320	1:240	N/A (died, prior testing attempts unsuccessful)
9	30	<i>Escherichia coli</i>	6 (% N/A)	6	1:1	Satisfactory§
10	89	Group B Streptococcus	650 (80%)	2220	1:3	N/A
11	40	<i>Escherichia coli</i>	3210 (95%)	2	1:6x10 ⁻⁴	Normal
12	6	<i>Escherichia coli</i>	960 (60%)	690	1:0.72	Satisfactory†
13	8	Group B Streptococcus	2030 (30%)	11310	1:6	Satisfactory†
14	2	Group B Streptococcus	10 (% N/A)	5500	1:550	Normal
15	5	Group B Streptococcus	2850 (40%)	1300	1:0.46	N/A
16	49	<i>Staphylococcus haemolyticus</i>	620 (90%)	2830	1:5	Satisfactory§

1
2
3 CSF, cerebrospinal fluid; WCC, white blood cell count; RCC, red blood cell count; SNHL, sensori-neural hearing loss; N/A, test not available
4 (not done or lost to follow up before determined).

5 *Normal hearing ≤ 20 dB; mild hearing loss 21-40 dB minimum detectable threshold; moderate 41-70 dB; severe loss 71-95 dB; profound loss
6 >95 dB

7 †Satisfactory hearing, based on oto-acoustic emissions and visual reinforcement audiometry with sound field testing down to 25 dB (no
8 audiogram), unable to rule out mild loss

9 ‡not further specified;

10 §Satisfactory hearing based on tone pip auditory brainstem responses/oto-acoustic emissions (no audiogram)

References

1. Stevens JP, Eames M, Kent A, et al. Long term outcome of neonatal meningitis. *Arch Dis Child Fetal Neonatal Ed.* 2003;88:F179-84. doi: 10.1136/fn.88.3.f179.
2. Public Health England. Guidelines for surveillance and audiological referral for infants and children following newborn hearing screen (Updated 19 July 2019) [Internet]. Available from: <https://www.gov.uk/government/publications/surveillance-and-audiological-referral-guidelines/guidelines-for-surveillance-and-audiological-referral-for-infants-and-children-following-newborn-hearing-screen> [Last accessed 2022 Aug 16]
3. Ku LC, Boggess KA, Cohen-Wolkowicz M. Bacterial meningitis in infants. *Clin Perinatol.* 2015;42:29-45, vii-viii. doi: 10.1016/j.clp.2014.10.004.
4. Paludetti G, Conti G, DI Nardo W, et al. Infant hearing loss: from diagnosis to therapy Official Report of XXI Conference of Italian Society of Pediatric Otorhinolaryngology. *Acta Otorhinolaryngol Ital.* 2012;32:347–70.

Review Only

BMJ Paediatrics Open

Sensorineural hearing loss after neonatal meningitis: a single centre retrospective study

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2022-001601.R2
Article Type:	Original research letter
Date Submitted by the Author:	25-Aug-2022
Complete List of Authors:	Sharma, Ankur; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit Leaf, James; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Thomas, Saumya; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit Cane, Christine; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Stuart, Claire; Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department Tremlett, Catherine; Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department Fitzgerald, John; Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology Clarke, Paul; Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit; University of East Anglia, Medical School
Keywords:	Audiology, Deafness, Neonatology, Microbiology, Epidemiology

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

TITLE:

Sensorineural hearing loss after neonatal meningitis: a single centre retrospective study

AUTHORS:

Ankur Sharma ¹ MRCPCH

James M Leaf ² MSc

Saumya Thomas ¹ MRCPCH

Christine Cane ²

Claire Stuart ³

Catherine Tremlett ³ MD MSc FRCPath

John Fitzgerald ² PhD BSc CS PFBSA

Paul Clarke ^{1,4} MD FRCPCH MRCP(UK)

Affiliations:

1. Norfolk and Norwich University Hospitals NHS Foundation Trust, Neonatal Intensive Care Unit, Norwich, UK

2. Norfolk and Norwich University Hospitals NHS Foundation Trust, Department of Audiology, Norwich, UK

3. Norfolk and Norwich University Hospitals NHS Foundation Trust, Microbiology Department, Norwich, UK

4. Norwich Medical School, University of East Anglia, Norwich, UK

Correspondence to: Prof P Clarke, ORCID ID: 0000-0001-6203-7632

Consultant Neonatologist, Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK. Email: paul.clarke@nnuh.nhs.uk

Tel: 01603 286337

Word count: 644

ABSTRACT

Babies in intensive care are at higher risk for meningitis and sensorineural hearing loss (SNHL). We reviewed the rate of SNHL among definite cases of bacterial/fungal meningitis in our neonatal intensive care unit over a 16-year period (2006-2021). We identified 16 confirmed meningitis cases among 16,070 admissions: 8 of 10 surviving infants with available diagnostic audiology had normal/satisfactory hearing while 2 of 10 had SNHL. Both infants with permanent hearing loss had been born extremely preterm and received potentially-ototoxic antimicrobials. Larger studies are needed to clarify whether SNHL occurs mainly due to meningitis itself or to its antimicrobial drug treatment.

1
2
3 Neonatal meningitis is a well-recognised risk factor for sensorineural hearing loss
4 (SNHL),[1] and indicates automatic referral for early auditory brainstem response testing and
5 other formal audiological testing.[2] There are no recent UK data reporting detailed hearing
6 outcomes of neonates who suffered neonatal meningitis. Our aim was to study the incidence
7 of SNHL in neonates admitted to our tertiary-level neonatal intensive care unit (NICU) with
8 proven meningitis.
9

10
11 We reviewed electronic neonatal records (BadgerNet, Clevermed, UK) and our local
12 microbiology database for the 16-year period 1/1/2006 to 31/12/2021 to identify all neonates
13 diagnosed with unequivocal bacterial or fungal meningitis. We defined proven meningitis
14 cases as those with positive bacterial or fungal growth on culture of cerebrospinal fluid (CSF)
15 obtained from infants with clinical signs of suspected meningitis/sepsis and who had received
16 at least 2 weeks of antibiotic therapy for the episode. We excluded any neonates with
17 meningitis who were never admitted to our NICU, those treated for suspected meningitis
18 despite a negative CSF culture, and cases of viral meningitis. Babies with CSF isolates of a
19 coagulase-negative Staphylococcus plus a concomitant CSF leucocyte count $<20 \times 10^6/L$ were
20 considered false positive cases and also excluded.[3] For all confirmed cases we reviewed
21 microbiological isolates, concomitant blood cultures, CSF cell counts, newborn hearing
22 screening results, and later diagnostic audiological testing at 0.5, 1, 2, and 4 kHz pure tone
23 audiometry thresholds. SNHL was diagnosed for infants with hearing loss thresholds >20
24 decibels.[4]
25

26
27 We had 16,070 neonatal admissions to our NICU during the 16-year study period.
28 Twenty-eight babies had a culture-positive CSF result and of these 16 were confirmed as
29 definite meningitis cases (Table 1). Twelve infants were born preterm and four were born at
30 term. Overall, the definite meningitis rate was 16/16,070 (0.1%), or 1 case per 1000
31 admissions. Fifteen were bacterial meningitis cases and one fungal. Three babies had
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 meningitis caused by a Coagulase-negative Staphylococcus. All except four babies had
4
5 concomitant blood cultures positive with the same organism. CSF specimens showed very
6
7 wide variation in white to red blood cell ratios (Table 1). The incidence of meningitis was
8
9 three-fold higher among preterm compared with term admissions, 12/7,185 vs. 4/8,885,
10
11 $p=0.02$, Chi² test). Two infants did not undergo newborn hearing screening (1 deceased, 1
12
13 contraindicated). Of 14 who underwent the screening, 9 had clear responses and 5 required
14
15 referral (1 bilateral, 4 unilateral screen fails).
16
17

18
19 Definitive follow-up audiology outcomes were unavailable for six babies (2 died in
20
21 infancy before completion of diagnostic testing; 2 had no formal testing despite meningitis
22
23 history; 2 failed to attend appointments).
24
25

26
27 Diagnostic audiology outcome data were available for 10 of the 14 surviving infants:
28
29 8 had hearing within normal limits (normal/satisfactory), and 2 have SNHL (1 severe
30
31 bilateral; 1 moderate mixed bilateral), a rate of SNHL among surviving neonatal meningitis
32
33 cases of at least 14% (2/14) (95% confidence limits: 2%, 43%). Both SNHL cases were
34
35 infants born extremely preterm who had suffered meningitis in their second postnatal week:
36
37 one had fungal meningitis caused by *Candida albicans*; one had bacterial meningitis caused
38
39 by *Staphylococcus epidermidis*. Their antimicrobial treatments included the potentially-
40
41 ototoxic agents flucytosine, vancomycin, and rifampicin.
42
43

44
45 Our single-centre series covering a 16-year period showed that the incidence of
46
47 definite meningitis among neonatal admissions was very low overall. SNHL caused by
48
49 neonatal meningitis (or its treatment) was thus relatively rare, with only two confirmed cases
50
51 in 16 years in our NICU. However, among cases of proven meningitis, the associated rate of
52
53 SNHL was not insignificant. A large epidemiological study - for example one linking
54
55 meningitis cases contained in large infection surveillance databases with hearing outcomes as
56
57 logged in national audiological databases - would provide a more accurate indication of
58
59
60

1
2
3 SNHL risk after neonatal meningitis. Such linking, along with related biochemical
4
5 antimicrobial therapeutic drug monitoring data, may also help to clarify whether SNHL
6
7 occurs mainly due to meningitis itself or to its antimicrobial drug treatment in extremely
8
9 preterm neonates.
10
11
12
13

14 **Contributorship**

15
16 PC devised this project. AS, ST and PC collected clinical data, JML, CC, and JF collected
17
18 audiological data, and CS interrogated the microbiological database. PC and CT reviewed
19
20 and adjudicated the meningitis cases, and JF provided audiological expertise. PC analysed the
21
22 data. PC and AS wrote the first manuscript draft and PC wrote the final draft. All authors
23
24 contributed to manuscript revisions. PC is guarantor.
25
26
27
28
29
30

31 **Patient and Public Involvement statement**

32
33 The research question arose as a direct result of a parent's question.
34
35
36
37

38 **Funding**

39
40 The authors declared no specific grant for this research from any funding agency in the
41
42 public, commercial or not-for-profit sectors.
43
44
45
46

47 **Competing interests**

48
49 The authors have no relevant competing interests to declare.
50
51
52
53

54 **Ethics approval**

55
56 This study reviewed routinely collected clinical data and did not require formal ethics review.
57
58
59
60

Exclusive License

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Paediatrics Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Table 1: Summary of baseline characteristics, CSF isolates and microscopy, and hearing outcomes of the 16 neonates with definite meningitis

Birth gestational age, completed weeks	28 (24 to 41; 25 to 38)
Birth weight, grammes	935 (589 to 3630; 740 to 2280)
Postnatal age at diagnosis, days	14 (2 to 89; 8 to 40)
Isolate, n cases:	
<i>Escherichia coli</i>	5
Group B Streptococcus	5
Coagulase-negative Staphylococcus	3*
<i>Pseudomonas aeruginosa</i>	1
<i>Enterobacter cloacae</i> complex	1
<i>Candida albicans</i>	1
CSF cell counts	
WCC, x10 ⁶ /L	745 (6 to 7420; 78 to 3015)
% polymorphs of total WCC	75% (0 to 95%; 40 to 90%)
RCC, x10 ⁶ /L	2525 (2 to 21600; 540 to 6520)
CSF ratio WCC:RCC	1:4 (1:550 to 1:6x10 ⁻⁴ ; 1:135 to 1:0.32)
Hearing outcomes†, n	
Sensorineural hearing loss	2
Normal	3
Satisfactory‡	5
N/A	6

Data are median (range; interquartile range).

CSF, cerebrospinal fluid; WCC, white blood cell count; RCC, red blood cell count; N/A, test not available (not done, died, or lost to follow up before determined).

*1 *Staphylococcus haemolyticus*. 1 *Staphylococcus epidermidis*, 1 not further speciated

†Normal hearing ≤20 dB; mild hearing loss 21-40 dB minimum detectable threshold; moderate 41-70 dB; severe loss 71-95 dB; profound loss >95 dB

‡Satisfactory hearing, based on oto-acoustic emissions and visual reinforcement audiometry with sound field testing down to 25 dB (no audiogram), but unable to rule out mild loss (n=3) or based on tone pip auditory brainstem responses/oto-acoustic emissions (no audiogram) (n=2)

References

1. Stevens JP, Eames M, Kent A, et al. Long term outcome of neonatal meningitis. *Arch Dis Child Fetal Neonatal Ed.* 2003;88:F179-84. doi: 10.1136/fn.88.3.f179.
2. Public Health England. Guidelines for surveillance and audiological referral for infants and children following newborn hearing screen (Updated 19 July 2019) [Internet]. Available from: <https://www.gov.uk/government/publications/surveillance-and-audiological-referral-guidelines/guidelines-for-surveillance-and-audiological-referral-for-infants-and-children-following-newborn-hearing-screen> [Last accessed 2022 Aug 25]
3. Ku LC, Boggess KA, Cohen-Wolkowicz M. Bacterial meningitis in infants. *Clin Perinatol.* 2015;42:29-45, vii-viii. doi: 10.1016/j.clp.2014.10.004.
4. Paludetti G, Conti G, DI Nardo W, et al. Infant hearing loss: from diagnosis to therapy
Official Report of XXI Conference of Italian Society of Pediatric Otorhinolaryngology.
Acta Otorhinolaryngol Ital. 2012;32:347–70.